Interleukin Genetics Sponsors Expert Meeting On The Role Of Inflammation In Aging
11/02/2006
INTERLEUKIN GENETICS SPONSORS EXPERT MEETING ON THE ROLE OF INFLAMMATION IN AGING
– Experts to discuss practical approaches to control over-expression of inflammation to extend healthy aging –
WALTHAM, MA – November 2, 2006 – Interleukin Genetics, Inc. (AMEX: ILI) today announced that it is co-sponsor of “Living Well to 100: Is Inflammation Central to Aging?” on November 6-7, 2006 in Boston, MA. The conference, supported by an educational grant from Interleukin Genetics and the Nutrilite Health Institute, is organized by the Tufts Health Care Institute, an affiliate of Tufts University School of Medicine, and the Friedman School of Nutrition Science and Policy of the Jean Mayer USDA Human Nutrition Research Center on Aging.
Increasing evidence supports the role of low-grade inflammation in many of the major diseases of aging, including cardiovascular disease, Alzheimer’s disease, osteoporosis and cancer. The Living Well to 100 Conference brings together leading experts from throughout the world to consider how the information on inflammation may be used to extend healthy aging. Panels of experts will address the role of inflammation in the development of common chronic diseases; inherited and environmental factors that regulate the expression of inflammation; and how lifestyle and nutrition can help individuals mitigate their risk of developing the common diseases of aging that are exacerbated by the inflammatory process.
“Excess inflammation is one of the key factors influencing an individual’s risk for various diseases as they age. Interleukin Genetics has long been involved in research related to the genetics of inflammation and its role in the aging process,” stated Ken Kornman, DDS, PhD Interleukin’s President and Chief Scientific Officer. “We now know that these genetic factors, infant nutrition, sleep patterns, and of course adult nutrition and exercise all determine an individual’s level of inflammation. Our goal is to bring genetic science to people while they are still healthy and can, through lifestyle changes, impact their over-expression of inflammation. We believe that this personalized approach has the potential to help individuals reduce pre-dispositions to medical complications later in life.”
“We are proud to participate in and support this second Living Well to 100 conference,” said Tim Richerson, Interleukin Genetics’ CEO. “We believe this focused conference offers elite researchers in various medical science fields an important forum to discuss and explore the role of inflammation in prolonging wellness as healthy individuals age. Healthy lifestyles and nutrition can help us all reduce our disease risk as we age.”
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing, acquiring, and commercializing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. In addition, Interleukin’s Alan James Group subsidiary sells nutraceutical brands, including Ginkoba™, Ginsana™, and Venastat™ through the nation’s largest food, drug and mass retailers. Interleukin’s current development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as its new proprietary OTCeutical™ products for distribution through the Alan James Group. Interleukin expects that these programs will also lead to the personalized selection of nutritional and therapeutic products, and provide consumers and healthcare professionals with better preventative product alternatives. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Janet Perry
(781) 398-0700